Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in adolescents and adults with cystic fibrosis and F508del-gating and F508del-residual function genotypes: results from an open-label extension study.
This phase 3 open-label extension study evaluated the long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in 251 adolescents and adults with cystic fibrosis and F508del-gating or…
Why it matters
The findings support the long-term safety and efficacy of ELX/TEZ/IVA in managing cystic fibrosis in adolescents and adults, highlighting its potential to improve lung function and overall health in this population.